Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results.

doi:10.1038/s41375-026-02972-9

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results.

Leukemia - 1 Sept 2026

Cortes Jorge E, Rea Delphine, Mauro Michael J, Hochhaus Andreas, Kim Dong-Wook, Sasaki Koji, Lang Fabian, Heinrich Michael C, Breccia Massimo, Deininger Michael, Goh Yeow-Tee, Janssen Jeroen J W M, Talpaz Moshe, Gómez García de Soria Valle, le Coutre Philipp, Mahon Francois-Xavier, DeAngelo Daniel J, Damon Andrea, Kapoor Shruti, Sanchez-Olle Gessami, Hoch Matthias, Agrawal Nithya, Quenet Sara, Hughes Timothy P

Abstract excerpt

In chronic myeloid leukemia in chronic phase (CML-CP), BCR::ABL1T315I commonly leads to treatment resistance, worse patient outcomes, and limited subsequent treatment options. By targeting the ABL1 myristoyl pocket, asciminib maintains activity against BCR::ABL1T315I. We report final long-term safety, tolerability, and efficacy results with asciminib in 48 patients with T315I-mutated CML-CP who received asciminib...

Read the complete abstract on PubMed